Mao Inhibitors

Concomitant use with other carbonic anhydrase inhibitors is not advisable due to possible additive effects.

Concomitant use of aliskiren with ACEIs in diabetic patients is contraindicated. In non-diabetics, avoid combined use particularly with CrCl <60 mL/min due to increased risk of hypotension, hyperkalemia, and renal failure.

Concomitant use with ACE inhibitors in diabetic patients is contraindicated. In non-diabetics, generally avoid combined use, especially with CrCl <60 mL/min, due to increased risk of hypotension, hyperkalemia, and acute renal failure.

MAOI antidepressants slow amphetamine metabolism, increasing effects on norepinephrine release causing hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur with fatal results.

MAOI antidepressants slow amphetamine metabolism, increasing norepinephrine release and risk of hypertensive crisis, toxic neurological effects, and potentially fatal malignant hyperpyrexia.

MAOIs slow amphetamine metabolism, potentiating effects and risk of hypertensive crisis, neurological toxicity, and potentially fatal malignant hyperpyrexia.

Apraclonidine should not be used in patients receiving MAO inhibitors.

Hyperpyrexia, hypotension, and death reported with coadministration. MAO inhibitors prolong/intensify anticholinergic effects and enhance pseudoephedrine effect.

Contraindicated due to increased risk of serotonin syndrome and/or elevated blood pressure. Use within 14 days before or after MAOI treatment is contraindicated.

Contraindicated in patients receiving MAO inhibitors (Type A or B).

Increased adrenergic tone risk. Use is contraindicated in patients receiving nonselective MAO inhibitors.

Clomipramine should not be used with MAO inhibitors.

Clomipramine should not be used with MAO inhibitors.

Life-threatening interaction with MAO inhibitors; contraindicated use.

Life-threatening interaction with MAO inhibitors; serotonin syndrome reported during combined use.

Life-threatening interactions with MAO inhibitors; serotonin syndrome reported.

Concomitant use with strong CYP3A4 inhibitors increases daridorexant exposure and risk of adverse reactions. Concomitant use is not recommended.

LEQSELVI is contraindicated in patients taking moderate or strong CYP2C9 inhibitors. Concomitant use increases deuruxolitinib exposure and may increase risk of serious adverse reactions such as thrombosis.

Dexmethylphenidate hydrochloride extended-release should not be used in patients being treated with MAO Inhibitors currently or within the preceding 2 weeks.

MAOIs slow amphetamine metabolism, increasing norepinephrine release and causing hypertensive crisis, toxic neurological effects, and potentially fatal malignant hyperpyrexia.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure. Do not use concomitantly or within 14 days after discontinuing MAOI.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure. Do not use concomitantly or within 14 days after discontinuing MAOI.

Slow amphetamine metabolism, potentiating effects and increasing norepinephrine release. Can cause hypertensive crisis, neurological toxicity, malignant hyperpyrexia, and potentially fatal results.

Contraindicated with CYP3A4 inhibitors including macrolide antibiotics and protease inhibitors.

Diphenoxylate may interact with MAOIs and precipitate hypertensive crisis. Avoid use and monitor for hypertensive crisis signs.

Potential additive effect on known systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.

Doxepin should not be administered in patients on MAOIs within the past two weeks.

Serious side effects and death reported with concomitant use. MAO inhibitors must be discontinued at least 2 weeks prior to initiating doxepin therapy.

Concomitant use should be avoided due to potential for increased blood pressure.

OATP1B1 inhibitors that significantly increase elagolix plasma concentrations are contraindicated due to increased risk of elagolix-associated adverse reactions.

Potent CYP3A4 inhibitors significantly increase eletriptan hydrobromide exposure. Should not be used within at least 72 hours of treatment with potent CYP3A4 inhibitors.

Strong CYP3A inhibitors are contraindicated in intermediate and poor CYP2D6 metabolizers due to increased eliglustat concentrations and cardiac arrhythmia risk.

Use of rilpivirine with proton pump inhibitors is contraindicated due to drugs increasing gastric pH, which may decrease rilpivirine plasma concentrations and loss of virologic response.

Use of RPV with proton pump inhibitors is contraindicated due to decreased plasma concentrations of RPV and loss of virologic response.

Use of RPV with proton pump inhibitors is contraindicated due to decreased plasma concentrations of RPV and loss of virologic response.

Strong CYP3A inhibitors are contraindicated with eplerenone due to increased metabolism inhibition.

Concomitant use may increase risk of angioedema. Avoid concomitant use.

Concomitant use of CYP1A2 inhibitors increases plasma Cmax and AUC of VEOZAH. VEOZAH is contraindicated in individuals using CYP1A2 inhibitors.

Concomitant use with strong CYP3A4 inhibitors increases finerenone exposure and may increase risk of adverse reactions.

Concomitant use of isosorbide dinitrate with phosphodiesterase inhibitors in any form is contraindicated.

Concomitant use of isosorbide mononitrate with phosphodiesterase inhibitors in any form is contraindicated.

Nonselective MAO inhibitors are contraindicated with levodopa. Discontinue at least two weeks prior to initiating levodopa.

MAOI antidepressants slow amphetamine metabolism, increasing monoamine release causing hypertensive crisis, toxic neurological effects, and potentially fatal malignant hyperpyrexia.

MAOI antidepressants slow amphetamine metabolism, increasing effects on norepinephrine release. Can cause hypertensive crisis, toxic neurological effects, and malignant hyperpyrexia with potentially fatal results.

MAOI antidepressants slow amphetamine metabolism, increasing norepinephrine release and causing hypertensive crisis, toxic neurological effects, and potentially fatal malignant hyperpyrexia.

Concomitant use with strong CYP3A inhibitors is contraindicated. May increase lonafarnib AUC and Cmax, increasing incidence and severity of adverse reactions including QTc interval prolongation.

Concomitant use increases mavacamten exposure, which may increase the risk of heart failure due to systolic dysfunction. Contraindicated.

Do not use methylphenidate hydrochloride within 2 weeks of MAO inhibitor use due to contraindication.

Increased risk of hypertension; concomitant use should be avoided.

Increased risk of hypertension; avoid concomitant use.

Avoid use with midodrine.

Co-administration increases mitapivat plasma concentrations, increasing risk of adverse reactions. Avoid concomitant use.

Concomitant use increases neratinib Cmax and AUC, increasing risk of NERLYNX toxicity. Avoid concomitant use.

Concomitant use of nitroglycerin with phosphodiesterase inhibitors in any form is contraindicated.

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium.

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Hyperpyrexia, hypotension, and death have been reported with coadministration of MAO inhibitors and dextromethorphan. Concomitant administration should be avoided.

Contraindicated due to increased risk of nonselective MAO inhibition that may lead to hypertensive crisis.

Contraindicated due to increased risk of nonselective MAO inhibition that may lead to hypertensive crisis.

Rizatriptan is contraindicated in patients taking MAO-A inhibitors due to increased systemic exposure.

Rizatriptan benzoate is contraindicated in patients taking MAO-A inhibitors. MAO-A inhibitors increase systemic exposure of rizatriptan and its metabolite.

Concomitant use is contraindicated due to increased risk of angioedema.

Avoid use of sildenafil with other PDE-5 inhibitors such as Viagra.

Avoid use with VIAGRA or other PDE-5 inhibitors.

Increases risk of severe and potentially fatal hyperkalemia, especially with other hyperkalemia risk factors. Avoid concomitant use.

Avoid concomitant use. Increased sparsentan exposure (2.7-12.3 fold), which may increase risk of adverse reactions.

MAO-A inhibitors increase systemic exposure of sumatriptan 7-fold. Use of sumatriptan in patients receiving MAO-A inhibitors is contraindicated.

MAO-A inhibitors increase sumatriptan systemic exposure by 7-fold, contraindicated for concurrent use.

MAO-A inhibitors increase systemic exposure of orally administered sumatriptan 7-fold. Use is contraindicated.

Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated. Strong CYP3A inhibitors increase suzetrigine and M6-SUZ exposures, which may cause adverse reactions.

Concomitant use profoundly affects triazolam clearance, resulting in increased concentrations and risk of adverse reactions. Do not administer together.

Dual blockade of RAS with ACE inhibitors and valsartan is associated with increased risks of hypotension, hyperkalemia, and acute renal failure. Avoid combined use.

Do not use moderate or strong CYP3A4 inhibitors with vardenafil as coadministration results in significant increases in plasma vardenafil concentrations.

MAO-A inhibitors increase systemic exposure of zolmitriptan and its active N-desmethyl metabolite. Concomitant use is contraindicated.

Concomitant use increases adagrasib concentrations before steady state, which may increase the risk of KRAZATI adverse reactions.

Both classes are vasodilators; concomitant use can potentially cause symptomatic hypotension. Caution is advised.

Carbonic anhydrase inhibitors may increase risk of lactic acidosis by decreasing serum bicarbonate and inducing metabolic acidosis.

Concomitant use may increase alpelisib exposure and risk of adverse reactions. Avoid use; if unavoidable, closely monitor for increased adverse reactions.

Increased risk of angioedema when used with benazepril.

In elderly, volume-depleted, or renally impaired patients, coadministration may result in deterioration of renal function including possible acute renal failure. May attenuate antihypertensive effect. Monitor renal function.

Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.

Fibrinolytic agents increase bleeding risk when coadministered with apixaban.

May potentiate cardiovascular effects of arformoterol. Use with extreme caution.

Increases asciminib Cmax and AUC, which may increase risk of adverse reactions. Closely monitor during concomitant use at 200 mg twice daily.

Coadministration increases avapritinib plasma concentrations, which may increase incidence and severity of adverse reactions. Avoid coadministration.

Concomitant use increases defactinib exposure, which may increase the risk of adverse reactions. Avoid concomitant use.

COX-2 inhibitors increase risk of renal dysfunction and acute renal failure when combined with azilsartan. Effects usually reversible. May attenuate antihypertensive effect.

Coadministration increases systemic exposure of bedaquiline, which may increase risk of adverse reactions. Closely monitor patient safety and liver function.

Increased risk of angioedema with concomitant use.

Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema.

Coadministration increases bortezomib exposure and may increase risk of bortezomib toxicities. Monitor for toxicity and consider dose reduction.

Avoid concomitant use. Increases bosutinib Cmax and AUC, which may increase risk of toxicities.

May potentiate systemic beta-blockade including decreased heart rate and depression.

Potential additive effect on known systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.

Increased incidence of serious infections and neutropenia risk when combined with TNF inhibitors. Concomitant use is not recommended.

Dual blockade of the RAS is associated with increased risks of hypotension, hyperkalemia, and acute renal failure. Monitor blood pressure, renal function, and electrolytes.

May result in deterioration of renal function, including possible acute renal failure, and may attenuate antihypertensive effect. Risk increased in elderly, volume-depleted, or renal-compromised patients.

Co-administration may result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. May attenuate antihypertensive effect.

Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure compared to monotherapy.

Concomitant administration can lead to severe hyperkalemia. Check serum potassium levels when ACE inhibitor therapy is altered.

May increase risk of hypotension and severe bradycardia due to catecholamine depletion.

May diminish antihypertensive effect; in elderly, volume depleted, or renally impaired patients may result in deterioration of renal function.

Increases risk of QT prolongation and ventricular arrhythmias compared to citalopram alone.

Increases risk of QT prolongation and ventricular arrhythmias. Maximum citalopram dosage is 20 mg daily when used concomitantly.

Increased hematotoxicity and immunosuppression may result from combined effect; ACE inhibitors can cause leukopenia.

MAO inhibitors prolong and intensify the anticholinergic effects of cyproheptadine.

Concomitant use with PPIs decreases dacomitinib concentrations, which may reduce VIZIMPRO efficacy. Avoid concomitant use.

Coadministration may increase dasatinib concentrations and risk of toxicity. Avoid concomitant use or consider dasatinib dose reduction.

Coadministration increases dexamethasone exposure, which may increase the risk of adverse reactions. Avoid concomitant use or closely monitor for adverse drug reactions.

May potentiate the action of diazepam. Careful consideration of pharmacology needed when combined.

Concomitant use may result in deterioration of renal function and acute renal failure, especially in elderly, volume-depleted, or renal-impaired patients.

May result in deterioration of renal function including possible acute renal failure in elderly, volume-depleted, or renally impaired patients. NSAIDs may diminish antihypertensive effect.

Risk of severe hypertension. Reduce recommended dopamine HCl injection dosage.

Strong CYP3A4 inhibitors increase dordaviprone exposure, which may increase the risk of MODEYSO-related adverse reactions. Avoid concomitant use or reduce MODEYSO dose if unavoidable.

Potential additive effect on systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.

Potential additive effect on systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.

Potential additive effect on systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.

Potential additive effect on systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.

Concomitant administration can result in additive blood pressure lowering effects and symptomatic hypotension.

Concomitant administration can result in additive blood pressure lowering effects and symptomatic hypotension.

Strong CYP3A inhibitors increase DRSP exposure, increasing risk of adverse reactions including hyperkalemia.

Co-administration may increase risk of myopathy and muscle injury. CPK elevation and myalgia occurred in patients on ELAFIBRANOR monotherapy.

Increased risk for angioedema in patients taking concomitant neprilysin inhibitors with enalapril maleate.

Concomitant neprilysin inhibitors may increase risk for angioedema in patients taking enalapril.

Potentiate the effects of epinephrine, may cause serious hypertension.

Potentiate the pressor effects of epinephrine.

Erythromycin increases concentrations of HMG-CoA reductase inhibitors.

Combined use should be avoided unless benefit of further lipid alterations outweighs increased risk of this drug combination.

May potentiate cardiovascular effects of formoterol. Use with extreme caution.

May potentiate cardiovascular effects of formoterol. Use with extreme caution.

Combined use of frovatriptan with MAO inhibitors has been reported to cause serotonin syndrome.

Synergistic effect expected when given concurrently with galantamine.

Synergistic effect expected when given concurrently with galantamine and other cholinesterase inhibitors.

Co-administration increases glasdegib plasma concentrations, raising risk of adverse reactions including QTc interval prolongation.

May increase effect of either the MAO inhibitor or hydrocodone; concomitant use has resulted in serotonin syndrome.

Initial small test dose advisable; concomitant use may cause excessive narcotic effects or MAOI interaction.

Concomitant use increases imlunestrant exposure, which may increase the risk of adverse reactions. Avoid concomitant use; if unavoidable, reduce imlunestrant dosage.

May result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renally impaired patients. May diminish antihypertensive effect.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Coadministration may result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. Antihypertensive effect may be attenuated.

COX-2 inhibitors can reduce diuretic and antihypertensive effects, and may result in deterioration of renal function including acute renal failure. Monitor renal function and blood pressure.

MAO inhibitors combined with isoflurane may increase risk of hemodynamic instability during surgery or medical procedures.

Co-administration increases ivosidenib plasma concentrations and may increase risk of QTc interval prolongation. Reduce TIBSOVO dose to 250 mg once daily if unavoidable.

Coadministration increases ixabepilone plasma concentration, increasing incidence and severity of adverse reactions. Avoid if possible; if unavoidable, reduce IXEMPRA dose.

Strong CYP3A4 inhibitors increase ribociclib exposure and may increase incidence and severity of adverse reactions including QTcF prolongation. Dose reduction required if coadministration cannot be avoided.

Coadministration may result in deterioration of renal function including possible acute renal failure; may attenuate antihypertensive effect.

COX-2 inhibitors may result in deterioration of renal function, including possible acute renal failure, in elderly patients, volume-depleted patients, or those with compromised renal function.

ACE inhibitor-induced sodium loss may increase serum lithium concentrations, increasing toxicity risk. Requires dose reduction and frequent monitoring.

Additive depression of the central nervous system when administered with lorazepam injection.

Avoid concomitant use with strong CYP3A inhibitors; reduce lorlatinib dose if unavoidable. Increases lorlatinib plasma concentrations, increasing adverse reactions.

May result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renal-impaired patients. Antihypertensive effect may be attenuated.

Dual blockade of RAS associated with increased risks of hypotension, syncope, hyperkalemia, and acute renal failure. Avoid combined use; if necessary, closely monitor blood pressure, renal function, and electrolytes.

Risk of deterioration of renal function including possible acute renal failure, and reduced diuretic and antihypertensive effects. Monitor renal function periodically.

Concomitant use increases mavorixafor Cmax and AUC, increasing risk of adverse reactions. Requires dosage reduction to 200 mg daily.

NSAIDs may diminish antihypertensive effects and result in renal function deterioration or acute renal failure in elderly, volume-depleted, or renally impaired patients.

Concomitant use may result in serotonin syndrome. Carefully observe patient, particularly during treatment initiation and dosage modification.

May increase risk of lactic acidosis with metformin. Consider more frequent monitoring.

May increase risk of lactic acidosis with metformin. Consider more frequent monitoring.

Inhibition of CYP3A4 increases methadone plasma concentration, resulting in increased opioid effects and risk of fatal overdose.

May increase methotrexate plasma concentrations, increasing risk of severe adverse reactions and potentially reducing clinical effectiveness.

Proton pump inhibitors may increase methotrexate plasma concentrations, increasing risk of severe adverse reactions.

Possible significant hypertension may theoretically occur up to 14 days following discontinuation of concomitant administration with irreversible MAO inhibitors.

Additive catecholamine-depleting effect with risk of hypotension and bradycardia. Possibly significant hypertension may occur up to 14 days after discontinuation.

COX-2 inhibitors may result in deterioration of renal function, including acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. Antihypertensive effect may be attenuated.

May potentiate effect on the cardiovascular system. Use with extreme caution.

Cases of serotonin syndrome reported with co-administration of triptans and MAO inhibitors. Risk of serious serotonergic adverse effects.

Concomitant use may increase risk of skeletal muscle effects. See WARNINGS section for additional details.

Concomitant use increases nilotinib concentrations, which may increase the risk of nilotinib toxicities. Avoid concomitant use or reduce nilotinib dose if coadministration cannot be avoided.

Gastric acid reducing agent. Decreases nirogacestat exposure, which may reduce effectiveness of nirogacestat.

Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if administration cannot be avoided.

Co-administration may result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renally impaired patients. Antihypertensive effect may be attenuated.

COX-2 inhibitors may result in deterioration of renal function including acute renal failure in elderly, volume-depleted, or renal-compromised patients. May attenuate antihypertensive effect.

May result in deterioration of renal function including possible acute renal failure and attenuate antihypertensive effect in elderly or volume-depleted patients.

Dual blockade of the renin-angiotensin system is associated with increased risks of hypotension, hyperkalemia, and acute renal failure. Avoid combined use.

Dual blockade of the RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure. Avoid combined use.

Concomitant use results in clinically significant increased exposure of omaveloxolone, which may increase the risk of adverse reactions. Avoid concomitant use; if unavoidable, dosage reduction with monitoring is recommended.

Increase plasma concentration of oxycodone, resulting in increased or prolonged opioid effects including respiratory depression.

Co-administration increases palovarotene exposure, which may increase risk of adverse reactions. Avoid concomitant use.

Coadministration increases pazopanib concentrations. Avoid coadministration; if unavoidable, reduce pazopanib dose.

Increased risk of angioedema with dual inhibition of renin-angiotensin system.

Antagonistic effects with decreased phenylephrine blood pressure effect.

Increases pimavanserin exposure. Reduce pimavanserin dose to 10 mg once daily when used concomitantly.

Concomitant administration increases pitolisant exposure by 2.2-fold. Reduce WAKIX dose by half.

Concurrent use increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other hyperkalemia risk factors.

RAAS inhibitors that produce potassium retention; monitor for hyperkalemia with concomitant use.

Produce potassium retention by inhibiting aldosterone production; closely monitor potassium levels.

Concomitant use increases pralsetinib exposure, which may increase the risk of adverse reactions. Avoid coadministration; if unavoidable, reduce GAVRETO dose.

Concomitant administration can result in additive blood pressure lowering effects and symptomatic hypotension.

Concomitant use in patients with reduced or absent CYP2D6 activity may increase primaquine exposure and risk of adverse reactions; defer initiation or increase monitoring.

Concomitant use with MAO inhibitors has been associated with increased incidence of extrapyramidal effects; this possibility should be considered.

Patients taking concomitant neprilysin inhibitor therapy may be at increased risk for angioedema.

Concomitant use increases remibrutinib exposure and risk of adverse reactions. Avoid concomitant use.

Concomitant use may increase repotrectinib exposure and increase incidence and severity of adverse reactions. Avoid concomitant use.

Closely monitor for toxicities including hepatic decompensation. Cases of fatal hepatic decompensation observed in cirrhotic patients. Dose reduction or discontinuation may be needed.

Strong CYP3A inhibitors increase ribociclib exposure, which may increase incidence and severity of adverse reactions including QTcF prolongation. Avoid concomitant use or reduce KISQALI dose.

Rifapentine induces CYP450 enzymes, causing significant decrease in plasma concentrations and loss of therapeutic effect of certain reverse transcriptase inhibitors.

Strong inhibitors of CYP3A4 may increase ruxolitinib systemic concentrations and increase risk of adverse reactions. Concomitant use should be avoided.

Concomitant use of MAO inhibitors and sevoflurane may increase the risk of hemodynamic instability during surgery or medical procedures.

Strong CYP2C9 inhibitors increase siponimod exposure; concomitant use is not recommended.

Concomitant use increases risk of severe and potentially fatal hyperkalemia, especially with other hyperkalemia risk factors. Avoid use; if unavoidable, closely monitor serum potassium.

ACE inhibitors increase hyperkalemia risk; avoid use due to potassium content or monitor serum potassium concentrations.

ACE inhibitors can increase serum potassium; concomitant use with spironolactone may lead to severe hyperkalemia. Check potassium levels when therapy is altered.

Concomitant administration may lead to severe hyperkalemia.

Concomitant use increases taletrectinib exposure, which may increase the risk of adverse reactions.

Concomitant use can potentially cause symptomatic hypotension.

COX-2 inhibitors may result in deterioration of renal function and reduce the diuretic, natriuretic, and antihypertensive effects similar to NSAIDs.

Concomitant use increases the risk of bleeding.

Concomitant use increases the risk of bleeding.

Substantial increase in tolvaptan exposure expected. Avoid co-administration.

Increased risk of hypotension and renal impairment.

Increase tramadol plasma concentration and may increase M1 levels via CYP2D6, risking seizures, serotonin syndrome, opioid toxicity, and potentially fatal respiratory depression.

Increase tramadol plasma concentration, potentially causing seizures, serotonin syndrome, opioid toxicity, and potentially fatal respiratory depression.

Concomitant use may increase tramadol plasma concentration and increase M1 levels, resulting in seizures, serotonin syndrome, and potentially fatal respiratory depression.

Increase tretinoin plasma concentrations, which may increase risk of adverse reactions. Avoid if possible; monitor frequently if unavoidable.

Increased risk of hyperkalemia when potassium-sparing agents like triamterene are used with ACE inhibitors.

Greatly increased risk of hyperkalemia when potassium-sparing agents used with ACE inhibitors. Serum potassium should be monitored frequently.

Potassium-sparing agents used with ACE inhibitors increase risk of hyperkalemia.

Concomitant use increases tucatinib plasma concentrations, which may increase the risk of TUKYSA toxicity.

Increased exposure to valbenazine and active metabolite, raising risk of exposure-related adverse reactions. Dose reduction to 40 mg once daily recommended.

Dual RAS blockade associated with increased risks of hypotension, hyperkalemia, and acute renal failure. Avoid combined use; closely monitor if necessary.

Reduce ALYFTREK dosage with concomitant use. CYP3A inhibitors increase vanzacaftor, tezacaftor, and deutivacaftor exposure, which may increase risk of adverse reactions.

Concomitant use may increase vorasidenib plasma concentrations and increase risk of adverse reactions.

Concomitant administration may result in significant increase in zavegepant exposure. Avoid concomitant administration.

Avoid concomitant use. Decreases ziftomenib exposure and may reduce efficacy of KOMZIFTI.

Concomitant use increases zuranolone exposure and may increase risk of ZURZUVAE-associated adverse reactions. Reduce ZURZUVAE dosage to 30 mg once daily.

Concomitant use with other carbonic anhydrase inhibitors is not advisable due to possible additive effects.

Concomitant use not advisable due to possible additive effects.

Alters urine pH toward acidic conditions, increasing amantadine elimination and reducing efficacy. Monitor for decreased effectiveness.

Concomitant use may increase cholinergic effects and increase risk of adverse reactions.

Co-administration results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for hypotension and edema.

Strong CYP2C8 inhibitors increase steady-state exposure of apalutamide active moieties. Dose reduction of apalutamide is recommended.

Caution should be used when concomitantly administering MAO inhibitors and armodafinil.

Aspirin may diminish the hyponatremic and hypotensive effects of ACE inhibitors through indirect effects on the renin-angiotensin pathway.

Aspirin may diminish the hyponatremic and hypotensive effects of ACE inhibitors through indirect effects on the renin-angiotensin pathway.

Aspirin may diminish hyponatremic and hypotensive effects of ACE inhibitors due to indirect effect on renin-angiotensin conversion pathway.

Reduce atazanavir plasma concentrations by increasing gastric pH, potentially reducing REYATAZ's therapeutic effect.

Proton pump inhibitors decrease belumosudil exposure and may reduce efficacy. Increase REZUROCK dosage to 200 mg twice daily when used concomitantly.

Coadministration increases belzutifan exposure. Monitor for anemia and hypoxia; reduce belzutifan dosage as recommended.

Coadministration may increase bendamustine plasma concentrations and increase incidence of adverse reactions. Consider alternative therapies.

Prolonged or accelerated half-life of metronidazole or concomitant medications; use with caution.

Coadministration increases brigatinib plasma concentrations, which may increase the incidence of adverse reactions. Dose reduction recommended if coadministration unavoidable.

Potential for additive effect on systemic effects of carbonic anhydrase inhibition. Concomitant administration not recommended.

Can increase plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects; discontinuation may result in decreased efficacy or withdrawal.

Increase buprenorphine plasma concentration, resulting in increased or prolonged opioid effects, particularly respiratory depression and sedation.

CYP3A inhibitors may increase rilpivirine plasma concentrations.

Coadministration with strong CYP3A inhibitors increased capmatinib exposure, which may increase the incidence and severity of adverse reactions. Closely monitor patients for adverse reactions.

Concomitant use increases exposures of cariprazine and its active metabolite didesmethylcariprazine. VRAYLAR dosage reduction is recommended.

Reduce gastric acidity and should be avoided as they may lower bioavailability of cefuroxime axetil.

Drugs which inhibit CYP2D6 also inhibit the metabolism of cevimeline, requiring caution in use.

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of clemastine fumarate.

CYP3A4 inhibitors may increase plasma concentrations of clindamycin. Monitor for adverse reactions in the presence of strong CYP3A4 inhibitors.

Strong CYP3A4 inhibitors may increase plasma concentrations of clindamycin; monitor for adverse reactions.

Concomitant administration may increase risk of cocaine toxicity due to reduced plasma cholinesterase activity affecting cocaine metabolism.

Cyclopentolate may interfere with the ocular anti-hypertensive action of ophthalmic cholinesterase inhibitors.

ACE inhibitors can cause leukopenia, potentiating cyclophosphamide's hematotoxicity and immunosuppression.

May increase risk of myopathy with elevated CPK levels when used concomitantly. Consider temporarily suspending HMG-CoA reductase inhibitors in patients receiving daptomycin.

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

Concomitant use increases diazoxide exposure, which may increase frequency and/or severity of adverse reactions. Dosage reduction of VYKAT XR recommended.

NSAIDs may diminish antihypertensive effect and may result in deterioration of renal function, especially in elderly, volume-depleted, or renally impaired patients.

Diclofenac may diminish antihypertensive effect and cause renal function deterioration in elderly, volume-depleted, or renal-impaired patients.

NSAIDs may diminish antihypertensive effect and may result in deterioration of renal function or acute renal failure in elderly, volume-depleted, or renally impaired patients.

NSAIDs may diminish antihypertensive effect. In elderly, volume-depleted, or renally impaired patients, may result in deterioration of renal function including acute renal failure.

When administered concomitantly, patients should be adequately hydrated and renal function assessed at baseline.

NSAIDs may diminish antihypertensive effect; in elderly, volume-depleted, or renally impaired patients, may cause renal function deterioration including acute renal failure.

May diminish antihypertensive effect; in elderly, volume-depleted, or renal impairment patients may result in deterioration of renal function.

NSAIDs may diminish antihypertensive effect and can cause renal impairment in elderly, volume-depleted, or renally impaired patients.

May increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride.

May impair digoxin excretion by declining GFR or tubular secretion. Monitor renal function and digoxin levels.

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of diphenhydramine hydrochloride.

Dipyridamole may counteract anticholinesterase effect of cholinesterase inhibitors, potentially aggravating myasthenia gravis.

CYP3A4 inhibitors may increase rilpivirine plasma concentrations. Monitor for adverse effects.

Absorption of tetracyclines is impaired by proton pump inhibitors.

May increase serum potassium concentration when used with drospirenone.

Inhibitors of CYP3A4 may increase estrogen plasma concentration by decreasing estrogen drug metabolism.

May cause significant increases or decreases in plasma concentrations of estrogen and progestin.

Significant changes (increase or decrease) in plasma concentrations of estrogen and progestin have been noted in some cases.

May cause significant changes (increase or decrease) in plasma concentrations of estrogen and progestin.

Coadministration increases duvelisib AUC, which may increase the risk of COPIKTRA toxicities. Reduce COPIKTRA dose to 15 mg twice daily.

CYP3A inhibitors may decrease clearance and increase plasma concentrations of cobicistat.

Coadministration increases entrectinib plasma concentrations, which could increase frequency or severity of adverse reactions. Dose reduction required for patients ≥2 years; avoid in patients <2 years.

NSAIDs may diminish antihypertensive effect; renal function deterioration possible in elderly, volume-depleted, or renally impaired patients.

Peripheral COMT inhibitors may interfere with Fluorodopa F18 imaging. Consider discontinuing 12 hours before administration if safely possible.

Elevate gastric pH and reduce gefitinib plasma concentrations. Avoid concomitant use if possible; if required, separate dosing by 12 hours.

May potentiate hypoglycemic action of glyburide. Patient should be observed closely for hypoglycemia when administered and for loss of control when withdrawn.

May increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.

May increase the glucose-lowering effect of glipizide, increasing susceptibility to hypoglycemia. Monitor closely.

MAO inhibitors should be used with caution in patients receiving hydralazine.

Icatibant may attenuate the antihypertensive effect of ACE inhibitors through pharmacodynamic interaction as a bradykinin B2 receptor antagonist.

FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors due to bradykinin B2 receptor antagonism.

Imatinib increases plasma concentration of certain HMG-CoA reductase inhibitors; use caution with drugs having narrow therapeutic window.

Imatinib increases plasma concentration of certain CYP3A4 metabolized HMG-CoA reductase inhibitors. Use caution with drugs that have narrow therapeutic window.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Suppress acid secretion and impair itraconazole capsule absorption. Use with caution and monitor antifungal activity.

Reduce gastric acidity and impair ketoconazole absorption from tablets. Ketoconazole should be taken with acidic beverage during coadministration.

NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking these drugs concomitantly.

Strong CYP3A4 inhibitors may significantly increase lacosamide exposure in patients with renal or hepatic impairment. Dose reduction may be necessary.

Patients with renal or hepatic impairment taking strong CYP3A4 inhibitors may have significant increase in lacosamide exposure. Dose reduction may be necessary.

Lanthanum carbonate may reduce bioavailability of ACE inhibitors. Do not administer within 2 hours of lanthanum carbonate dosing.

Increased risk of serotonin syndrome when combined with lasmiditan; use with caution.

ACE inhibitors may increase risk of hyperkalemia when used with CLINIMIX E due to its potassium content; administer with caution.

Significant changes in plasma levels of estrogen and progestin have been noted with co-administration.

May cause hypochlorhydria and affect intragastric pH, reducing levothyroxine absorption. Monitor patients appropriately.

Increases lumateperone exposure, which may increase risk of adverse reactions. Reduce CAPLYTA dosage to 10.5 mg once daily.

Potential for drug-drug interactions as meclizine is metabolized by CYP2D6; monitor for adverse reactions and clinical effect.

Potential for drug-drug interaction as meclizine is metabolized by CYP2D6; monitor for adverse reactions and clinical effect.

Significant changes (increase or decrease) in plasma progestin levels may occur with co-administration.

Meloxicam may diminish antihypertensive effect and in elderly/volume-depleted/renal impairment patients may result in renal function deterioration. Monitor blood pressure and renal function.

Carbonic anhydrase inhibitors alter urine pH towards alkaline conditions, reducing memantine clearance by about 80% and potentially leading to drug accumulation and increased adverse effects.

Carbonic anhydrase inhibitors alter urine pH towards alkaline conditions, which may reduce memantine clearance by about 80% and lead to drug accumulation and increased adverse effects.

Carbonic anhydrase inhibitors may alter urine pH towards alkaline conditions, reducing memantine clearance by about 80% and leading to drug accumulation.

Concomitant use increases meperidine plasma concentration, resulting in increased or prolonged opioid effects and respiratory depression risk. Dosage reduction may be necessary.

May increase methamphetamine exposure and increase risk of serotonin syndrome. Monitor for signs and symptoms during initiation and dosage increases.

CYP inhibitors may cause prolonged half-life of metronidazole or concomitant medications. Monitor for effects.

Concomitant use may increase unconjugated DM4 exposure, increasing the risk of ELAHERE adverse reactions. Closely monitor patients for adverse reactions.

Caution should be used when concomitantly administering MAO inhibitors and modafinil.

NSAIDs may diminish the antihypertensive effect of ACE inhibitors.

NSAIDs may diminish the antihypertensive effect of ACE inhibitors.

Strong CYP3A inhibitors increase exposure of nerandomilast, which may increase the risk of JASCAYD adverse reactions. Dosage reduction to 9 mg twice daily is recommended.

CYP3A4 inhibitors may alter the first pass or clearance of nimodipine, potentially increasing nimodipine levels.

May cause significant increases or decreases in plasma levels of estrogen and progestin, potentially decreasing contraceptive effectiveness.

Concomitant use increases olanzapine AUC and Cmax, which may increase the risk of LYBALVI adverse reactions. Consider reducing the dosage of olanzapine component.

Strong CYP3A4 inhibitors may inhibit metabolism of mometasone furoate, increasing plasma concentration and risk of adverse reactions.

Aspirin may diminish hypotensive and hyponatremic effects of ACE inhibitors through indirect effect on renin-angiotensin conversion pathway.

Caution advised in patients taking MAO inhibitors which can affect metabolism and uptake of circulating amines.

Caution advised in patients taking MAO inhibitors which can affect metabolism and uptake of circulating amines.

Concomitant use demonstrates dose-dependent decrease in paltusotine exposure. Patients on PALSONIFY 60 mg should avoid concomitant use; others may require dosage increase.

Inhibitors may increase phenobarbital exposure, increasing risk of adverse reactions. Closely monitor and consider dosage adjustment.

Simultaneous administration may potentiate effects; caution should be exercised due to additive cholinesterase inhibition.

Increases pimavanserin exposure; dosage reduction of NUPLAZID required.

May diminish antihypertensive effect and in elderly, volume depleted, or renally impaired patients may result in renal function deterioration.

May produce unfavorable interactions with potassium supplements, risk of hyperkalemia.

Concomitant administration with PDE-5 inhibitors results in additive blood pressure lowering effects and symptomatic hypotension.

ACE inhibitors combined with beta-blockers can cause hypotension, particularly during acute myocardial infarction.

Concomitant neprilysin inhibitor therapy may increase risk for angioedema.

Carbonic-anhydrase inhibitors alkalinize urine and reduce renal elimination of quinidine.

Alkalinize urine and reduce renal elimination of quinidine, increasing quinidine levels.

Concomitant use increases quizartinib systemic exposure, which may increase risk of adverse reactions. VANFLYTA dosage reduction recommended.

Concomitant use increases revumenib systemic exposure, which may increase the risk of adverse reactions. Dose reduction of REVUFORJ is required.

Proton pump inhibitors decrease rilzabrutinib exposure due to pH-dependent solubility, potentially reducing efficacy. Avoid concomitant use.

Coadministration increases ripretinib and active metabolite (DP-5439) exposure, which may increase the risk of adverse reactions. Monitor patients more frequently.

PPIs may cause faster drug release and increase risedronate bioavailability. Concomitant administration is not recommended.

Co-administration may increase roflumilast systemic exposure and may result in increased adverse reactions. Weigh potential for increased adverse reactions against benefit.

Strong CYP2C9 inhibitors increase seladelpar exposure. Monitor patients for adverse effects during concomitant use.

Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministration; if unavoidable, take RETEVMO with food.

Avoid use due to potassium content increasing risk of hyperkalemia. If unavoidable, monitor serum potassium concentrations.

Co-administration may increase sunitinib plasma concentrations. Consider dose reduction of sunitinib malate.

BCRP inhibitors may increase talazoparib exposure; monitor for increased adverse reactions and modify dosage as recommended.

COX-2 inhibitors may deteriorate renal function and cause acute renal failure in elderly, volume-depleted, or renally compromised patients. May attenuate antihypertensive effect. Monitor renal function periodically.

Potential additive effect on systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.

CYP3A4 inhibitors may increase tinidazole levels. Monitor for increased adverse reactions.

Concomitant use may increase unconjugated MMAE exposure, increasing risk of TIVDAK adverse reactions. Close monitoring for adverse reactions recommended.

NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. This interaction should be given consideration in patients taking both drugs concomitantly.

Monitor patient for appearance or worsening of metabolic acidosis when co-administered with other carbonic anhydrase inhibitors.

Strong CYP3A4 inhibitors may increase tradipitant exposure and the risk of adverse reactions.

Tropicamide may interfere with the antihypertensive action of ophthalmic cholinesterase inhibitors.

Concomitant use increases venlafaxine and ODV levels, which may increase toxicity risk. Consider reducing venlafaxine dose.

Increase Cmax and AUC of venlafaxine and ODV, which may increase toxicity risk. Consider reducing venlafaxine dose.

Increases Cmax and AUC of venlafaxine and O-desmethylvenlafaxine, potentially increasing toxicity risk. Consider dose reduction.

Concomitant use is not recommended due to potential for hypotension.

Drugs that decrease clotting, vasoconstriction or platelet aggregation could decrease the efficacy of VISUDYNE therapy.

Concurrent administration may cause earlier onset and/or increased severity of adverse reactions. Exercise caution in patients concurrently taking CYP3A inhibitors.

Coadministration increases zanubrutinib Cmax and AUC, which may increase the risk of BRUKINSA toxicities. Dose reduction recommended.

Concomitant use increased zolpidem exposure. Consider using lower zolpidem dose.

Concomitant use may increase severity of metabolic acidosis and increase risk of kidney stone formation. Monitor for metabolic acidosis.

Administered concomitantly in clinical trials without evidence of clinically meaningful effect on belimumab pharmacokinetics.

Insufficient experience to assess safety and efficacy when administered concurrently with other biologic therapy. Use not recommended.

May cause significant changes (increase or decrease) in plasma concentrations of estrogen and progestin.

KEVZARA has not been investigated in combination with JAK inhibitors; concomitant use not studied.